These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32841498)

  • 1. Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels.
    Schaefer B; Hausfeld A; Martin M; Steele P; Martin J; Reher SR; Lane A; Luchtman-Jones L
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28654. PubMed ID: 32841498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
    Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
    Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of heparins in antithrombin-deficient patients.
    Croles FN; Lukens MV; Mulder R; de Maat MPM; Mulder AB; Meijer K
    Thromb Res; 2019 Mar; 175():8-12. PubMed ID: 30660948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and evaluation a new generation of low molecular weight heparin.
    Zhao D; Sang Q; Cui H
    Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
    Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
    Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Description of anti-Xa monitoring practices during low molecular weight heparin use.
    Lin A; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):623-628. PubMed ID: 31317300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.
    Ryerson LM; Bauman ME; Kuhle S; Bruce AA; Massicotte MP
    Pediatr Crit Care Med; 2014 Oct; 15(8):e340-6. PubMed ID: 24901804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
    Malikova I; Husakova M; Bilkova J; Brzezkova R; Hrachovinova I; Kvasnicka T
    Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study.
    Boban A; Paulus S; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2017 Apr; 28(3):199-204. PubMed ID: 27254442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis.
    Wong SS; Lau WY; Chan PK; Wan CK; Cheng YL
    Nephrology (Carlton); 2017 Nov; 22(11):921-924. PubMed ID: 28767200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.